Ann Clin Case Rep | Volume 8, Issue 1 | Case Report | Open Access

Exacerbation of Psoriasis after Alectinib Treatment

Qiuyang Xu1, Yangyang Li2, Yang N1, Chen L1 and Wang J1*

1Department of Dermatology and Venereology, The First Affiliated Hospital of Wenzhou Medical University, China
2Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, China

^*Correspondance to: Jingying Wang 

Abstract

Alectinib, a highly selective tyrosine kinase inhibitor of Anaplastic Lymphoma Kinase (ALK), has shown significant efficacy in the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC). Skin and subcutaneous tissue disorders induced by alectinib have been reported, including rash, maculopapular rash and more. Psoriasis is a chronic, systemic, inflammatory disorder, in which an increased release of pro-inflammatory cytokines and chronic activation of the innate and adaptive immune systems can cause cutaneous and systemic manifestations and significant negative effects on patient quality of life. However, little is known about the effect of alectinib on aggravating psoriasis. Here, we report a 59-year-old male whose pre-existing psoriasis was exacerbated following the administration of alectinib to treat metastatic lung adenocarcinoma.

Citation:

Qiuyang Xu, Yangyang Li, Yang N, Chen L, Wang J. Exacerbation of Psoriasis after Alectinib Treatment. Ann Clin Case Rep. 2023; 8: 2380..